. 2015 Jun 19;10(7):1300–1310. doi: 10.2215/CJN.01910215

Table 1.

Drugs commonly implicated in ANCA-associated vasculitis

Drug	Evidence	Renal Involvement	Comments
Cocaine and levamisole	Multiple case series and case reports	44%^a	Skin manifestations in 61%^a
Cocaine and levamisole	Multiple case series and case reports	44%^a	Neutropenia in 28%^a
Hydralazine	Case series and case reports	80%–90%^b	Combined pulmonary-renal syndrome is rare (15 patients to date)
Hydralazine	Case series and case reports	80%–90%^b	Lupus-like syndrome is common
Antithyroid medications	PTU: multiple case series and case reports	May be common	Animal models also support association with PTU
Antithyroid medications	Carbimazole and methimazole: case reports	May be common	Animal models also support association with PTU
Minocycline	Small case series and case reports	No reported cases of renal involvement with small-vessel vasculitis	Conflicting data on ANCA seroconversion with minocycline use (45,46)
Minocycline	Small case series and case reports	PAN with p-ANCA positivity and renal involvement reported
Allopurinol	Case reports	Reported	Pulmonary-renal syndrome rarely reported
Penicillamine	Case reports	Reported	No seroconversion noted in analysis of scleroderma trial (46)
Sulfasalazine	Case reports	Reported	Pulmonary-renal syndrome also reported
Sulfasalazine	Case reports	Reported	No seroconversion noted in analysis of the CSSRD Trial (46)

PTU, propylthiouracil; PAN, polyarteritis nodosa; p-ANCA, perinuclear ANCA; CSSRD, Cooperative Systematic Studies of the Rheumatic Diseases.

Data from the largest case series of cocaine- and levamisole-associated, ANCA-associated vasculitis (21).

Data from the largest series of hydralazine-associated, ANCA-associated vasculitis (5,38).